Abstract
Pregnancy-induced hypertension (PIH) is a life-threatening disorder for both mother and fetus; cardiac dysfunction is the major complication and can result in further deterioration. Recently, it has been recognized that aberrant activation of angiotensin type 1 receptor (AT1) signaling contributes to the pathogenesis of PIH, but the details of the relationship between cardiac injury and enhanced AT1 signaling in PIH are still unclear. We previously generated a transgenic mouse model of pregnancy-associated hypertension (PAH) via overproduction of angiotensin II, an endogenous ligand of AT1, in the maternal circulation during late pregnancy. In the present study, we administered olmesartan, an AT1 blocker, to suppress redundant AT1 signaling in PAH mice and evaluated the efficacy of this treatment in cardiac remodeling. Olmesartan treatment significantly lowered the blood pressure of PAH mice, and hypertrophy as well as increased plasma levels of cardiac injury markers were also markedly reduced. Histological analyses revealed that morphological abnormalities and fibrosis in the hearts of PAH mice recovered to the levels of normal pregnant wildtype mice after the administration of olmesartan. Moreover, in fibrotic regions of PAH hearts, olmesartan treatment significantly decreased the extent of cardiac injury and apoptosis. These results indicate that the activation of AT1 signaling pathways during maternal hypertension plays a critical role in cardiac remodeling in PAH mice, and suggest that treatment with an AT1 blocker could effectively ameliorate cardiac dysfunction during pregnancy with hypertension in vivo.
Similar content being viewed by others
Article PDF
References
National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy: Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 2000; 183: S1–S22.
Lavoie JL, Sigmund CD : Minireview: overview of the renin-angiotensin system—an endocrine and paracrine system. Endocrinology 2003; 144: 2179–2183.
Paul M, Mehr AP, Kreutz R : Physiology of local reninangiotensin systems. Physiol Rev 2006; 86: 747–803.
Nasjletti A, Masson GMC : Studies on angiotensinogen formation in a liver perfusion system. Circ Res 1972; 30: 187–202.
Tewksbury DA : Angiotensinogen-biochemistry and molecular biology. in Laragh JH, Brenner BM (eds): Hypertension: Pathophysiology, Diagnosis and Management. New York, Raven Press, 1990, pp 1197–1216.
Chen Y, Naftilan AJ, Oparil S : Androgen-dependent angiotensinogen and renin messenger RNA expression in hypertensive rats. Hypertension 1992; 19: 456–463.
Rubattu S, Quimby FW, Sealey JE : Tissue renin and prorenin increase in female cats during the reproductive cycle without commensurate changes in plasma, amniotic or ovarian follicular fluid. J Hypertens 1991; 9: 525–535.
Glorioso N, Atlas SA, Laragh JH, et al: Prorenin in high concentrations in human ovarian follicular fluid. Science 1986; 233: 1422–1424.
Howard RB, Pucell AG, Bumpus FM, et al: Rat ovarian renin: characterization and changes during the estrous cycle. Endocrinology 1988; 123: 2331–2340.
Brown MA, Wang J, Whitworth JA : The renin-angiotensinaldosterone system in pre-eclampsia. Clin Exp Hypertens 1997; 19: 713–726.
Baker PN, Pipkin FB, Symonds EM : Platelet angiotensin II binding and plasma renin concentration, plasma renin substrate and plasma angiotensin II in human pregnancy. Clin Sci (Lond) 1990; 79: 403–408.
Baker PN, Pipkin FB, Symonds EM : Comparative study of platelet angiotensin II binding and the angiotensin II sensitivity test as predictors of pregnancy-induced hypertension. Clin Sci (Lond) 1992; 83: 89–95.
Gant NF, Daley GL, Chand S, et al: A study of angiotensin II pressor response throughout primigravid pregnancy. J Clin Invest 1973; 52: 2682–2689.
Chesley LC, Talledo E, Bohler CS, et al: Vascular reactivity to angiotensin II and norepinephrine in pregnant and nonpregnant women. Am J Obstet Gynecol 1965; 91: 837–842.
Crowley SD, Tharaux PL, Audoly LP, et al: Exploring type I angiotensin (AT1) receptor functions through gene targeting. Acta Physiol Scand 2004; 181: 561–570.
AbdAlla S, Lother H, el Massiery A, et al: Increased AT1 receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness. Nat Med 2001; 7: 1003–1009.
Wallukat G, Homuth V, Fischer T, et al: Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest 1999; 103: 945–952.
Zhou CC, Zhang Y, Irani RA, et al: Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice. Nat Med 2008; 14: 855–862.
Takimoto E, Ishida J, Sugiyama F, et al: Hypertension induced in pregnant mice by placental renin and maternal angiotensinogen. Science 1996; 274: 995–998.
Saito T, Ishida J, Takimoto-Ohnishi E, et al: An essential role for angiotensin II type 1a receptor in pregnancy-associated hypertension with intrauterine growth retardation. FASEB J 2004; 18: 388–390.
Takimoto-Ohnishi E, Saito T, Ishida J, et al: Differential roles of renin and angiotensinogen in the feto-maternal interface to the development of complications of pregnancy. Mol Endocrinol 2005; 19: 1361–1372.
Furuya M, Ishida J, Inaba S, et al: Impaired placental neovascularization in mice with pregnancy-associated hypertension. Lab Invest 2008; 88: 416–429.
Ishida J, Hashimoto T, Hashimoto Y, et al: Regulatory roles for APJ, a seven-transmembrane receptor related to angiotensin-type 1 receptor in blood pressure in vivo. J Biol Chem 2004; 279: 26274–26279.
Ishizaka N, Saito K, Mitani H, et al: Iron overload augments angiotensin II-induced cardiac fibrosis and promotes neointima formation. Circulation 2002; 106: 1840–1846.
Garpvic VD, Hayman SR : Hypertension in pregnancy: an emerging risk factor for cardiovascular disease. Nat Clin Pract Nephrol 2007; 11: 613–622.
Abboud J, Murad Y, Chen-Scarabelli C, Saravolatz L, Scarabelli TM : Peripartum cardiomyopathy: a comprehensive review. Int J Cardiol 2007; 118: 295–303.
Hunter S, Robson SC : Adaptation of the maternal heart in pregnancy. Br Heart J 1992; 68: 540–543.
Mesa A, Carlos J, Hernandez A, et al: Left ventricular diastolic function in normal human pregnancy. Circulation 1999; 9: 511–517.
Valensise H, Novelli GP, Vasapollo B, et al: Maternal diastolic dysfunction and left ventricular geometry in gestational hypertension. Hypertension 2001; 37: 1209–1215.
Novelli GP, Valensise H, Vasapollo B, et al: Left ventricular concentric geometry as a risk factor in gestational hypertension. Hypertension 2003; 41: 469–475.
Valensise H, Vasapollo B, Novelli GP, et al: Maternal totalvascular resistance and concentric geometry: a key to identify uncomplicated gestational hypertension. BJOG 2006; 113: 1044–1052.
Zheng J, Bird IM, Chen DB, et al: Angiotensin II regulation of ovine fetoplacental artery endothelial functions: interactions with nitric oxide. J Physiol 2005; 565: 59–69.
Hanssens M, Keirse MJ, Spitz B, et al: Angiotensin II levels in hypertensive and normotensive pregnancies. Br J Obstet Gynecol 1991; 98: 155–161.
Kalenga MK, Thomas K, de Gasparo M et al: Determination of renin, angiotensin converting enzyme and angiotensin II levels in human placenta, chorion and amnion from women with pregnancy induced hypertension. Clin Endocrinol (Oxf) 1996; 44: 429–433.
Sadoshima J, Izumo S : Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype. Circ Res 1993; 73: 413–423.
Hein L, Stevens ME, Barsh GS, et al: Overexpression of angiotensin AT1 receptor transgene in the mouse myocardium produces a lethal phenotype associated with myocyte hyperplasia and heart block. Proc Natl Acad Sci U S A 1997; 94: 6391–6396.
Paradis P, Dali-Youcef N, Paradis FW, et al: Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling. Proc Natl Acad Sci U S A 2000; 97: 931–936.
Kudoh S, Komuro I, Hiroi Y, et al: Mechanical stretch induces hypertrophic responses in cardiac myocytes of angiotensin II type 1a receptor knockout mice. J Biol Chem 1998; 273: 24037–24043.
Berk BC, Fujiwara K, Lehoux S : ECM remodeling in hypertensive heart disease. J Clin Invest 2007; 117: 568–575.
Burstein B, Nattel S : Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol 2008; 51: 802–809.
Crabos M, Roth M, Hahn AW, et al: Characterization of angiotensin II receptors in cultured adult rat cardiac fibroblasts. Coupling to signaling systems and gene expression. J Clin Invest 1994; 93: 2372–2378.
Harada K, Sugaya T, Murakami K, Yazaki Y, Komuro I : Angiotensin II type 1A receptor knockout mice display less left ventricular remodeling and improved survival after myocardial infarction. Circulation 1999; 100: 2093–2099.
Lijnen PJ, Petrov VV, Fagard RH : Angiotensin II-induced stimulation of collagen secretion and production in cardiac fibroblasts is mediated via angiotensin II subtype 1 receptors. J Renin Angiotensin Aldosterone Syst 2001; 2: 117–122.
Tokuda K, Kai H, Kuwahara F, et al: Pressure-independent effects of angiotensin II on hypertensive myocardial fibrosis. Hypertension 2004; 43: 499–503.
Kabour A, Henegar JR, Devineni VR, Janicki JS : Prevention of angiotensin II induced myocyte necrosis and coronary vascular damage by lisinopril and losartan in the rat. Cardiovasc Res 1995; 29: 543–548.
Nakamura K, Fushimi K, Kouchi H, et al: Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-alpha and angiotensin II. Circulation 1998; 98: 794–799.
Nishida M, Tanabe S, Maruyama Y, et al: Gα12/13- and reactive oxygen species–dependent activation of c-Jun NH2-terminal kinase and p38 mitogen-activated protein kinase by angiotensin receptor stimulation in rat neonatal cardiomyocytes. J Biol Chem 2005; 280: 18434–18441.
Skultetyova D, Filipova S, Riecansky I, et al: The role of angiotensin type 1 receptor in inflammation and endothelial dysfunction. Recent Patents Cardiovasc Drug Discov 2007; 2: 23–27.
Schulz R, Heusch G : Angiotensin II in the failing heart. Kidney Blood Press Res 2005; 28: 349–352 (Short Communication).
Ohkuchi A, Hirashima C, Matsubara S, et al: Alterations in placental growth factor levels before and after the onset of preeclampsia are more pronounced in women with early onset severe preeclampsia. Hypertens Res 2007; 30: 151–159.
Hirashima C, Ohkuchi A, Arai F, et al: Establishing reference values for both total soluble fms-like tyrosine kinase 1 and free placental growth factor in pregnant women. Hypertens Res 2005; 28: 727–732.
Maynard SE, Min JY, Merchan J, et al: Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111: 649–658.
Lu F, Longo M, Tamayo E, et al: The effect of over-expression of sFlt-1 on blood pressure and the occurrence of other manifestations of preeclampsia in unrestrained conscious pregnant mice. Am J Obstet Gynecol 2007; 196: 396.e1–396.e7.
Zhou CC, Ahmad S, Mi T, et al: Autoantibody from women with preeclampsia induces soluble Fms-like tyrosine kinase-1 production via angiotensin type 1 receptor and calcineurin/nuclear factor of activated T-cell signaling. Hypertension 2008; 51: 1010–1019.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sakairi, A., Ishida, J., Honjo, K. et al. Angiotensin Type 1 Receptor Blockade Prevents Cardiac Remodeling in Mice with Pregnancy-Associated Hypertension. Hypertens Res 31, 2165–2175 (2008). https://doi.org/10.1291/hypres.31.2165
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1291/hypres.31.2165
Keywords
This article is cited by
-
Association of maternal angiotensin II type 1 and type 2 receptor combination genotypes with susceptibility to early-onset preeclampsia
Journal of Human Hypertension (2022)